AG
SWTX

Algert Global’s SpringWorks Therapeutics SWTX Stock Holding History

Algert Global’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-44,180
Closed -$1.95M – 1340
2025
Q1 		$1.95M Buy
44,180
+8,840
+25% +$407K 0.05% 605
2024
Q4 		$1.28M Buy
+35,340
New +$1.23M 0.03% 729
2024
Q3 		– Sell
-34,989
Closed -$1.32M – 1567
2024
Q2 		$1.32M Buy
34,989
+13,489
+63% +$568K 0.04% 602
2024
Q1 		$1.06M Sell
21,500
-12,480
-37% -$577K 0.04% 598
2023
Q4 		$1.24M Buy
+33,980
New +$887K 0.05% 563
2023
Q2 		– Sell
-19,184
Closed -$494K – 1256
2023
Q1 		$494K Buy
19,184
+954
+5% +$27.9K 0.02% 824
2022
Q4 		$474K Buy
+18,230
New +$449K 0.03% 818

Other funds holding SWTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Algert Global's SWTX Position: Q2 2025 in Review

Algert Global sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 44,180 shares — an estimated $1.95M sold.

Algert Global first reported a position in SWTX in Q4 2022 and held it in 7 quarters. The position peaked at $1.95M in Q1 2025. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Algert Global reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Algert Global sold 44,180 SpringWorks Therapeutics shares in Q2 2025, an estimated $1.95M.
  • Algert Global first reported a position in SpringWorks Therapeutics in Q4 2022 and held it in 7 quarters.
  • Algert Global's SpringWorks Therapeutics position peaked at $1.95M in Q1 2025.
  • 223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Algert Global's 13F filing for Q2 2025, filed 14 Aug 2025.